The Biology of Chronic Myelogenous Leukemia Progression: Who, What, Where, and Why?

Hematology/Oncology Clinics of North America

Volumn 25, Issue 5, 2011, Pages 967-980

  Radich, Jerald P ^a  

^a USA   (United States)

Author keywords

Blast crisis; Chronic myeloid leukemia; Genetic instability; Progression

Indexed keywords

DASATINIB; FINGOLIMOD; FORSKOLIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYCHLOROQUINE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ALLOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GENE;

BLAST CRISIS; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 80755189382     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.002     Document Type: Review

References (80)

1. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102(1):276-283.
2. Soverini S., Martinelli G., Rosti G., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005, 23(18):4100-4109.
3. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7(6):441-453.
4. Perrotti D., Jamieson C., Goldman J., et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120(7):2254-2264.
5. O'Brien S., Berman E., Bhalla K., et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw 2007, 5(5):474-496.
6. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103(8):2794-2799.
7. Au W.Y., Caguioa P.B., Chuah C., et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009, 89(1):14-23.
8. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(9):3472-3475.
9. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17(12):2401-2409.
10. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2):117-125.
11. Koptyra M., Falinski R., Nowicki M.O., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108(1):319-327.
12. Chu S., Xu H., Shah N.P., et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105(5):2093-2098.
13. Jiang X., Saw K.M., Eaves A., et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007, 99(9):680-693.
14. Collins S.J., Groudine M.T. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood 1987, 69(3):893-898.
15. Huntly B.J., Bench A.J., Delabesse E., et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002, 99(12):4547-4553.
16. Huntly B.J., Guilhot F., Reid A.G., et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003, 102(6):2205-2212.
17. Sawyers C.L., McLaughlin J., Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995, 181(1):307-313.
18. Ilaria R.L., Van Etten R.A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271(49):31704-31710.
19. Shuai K., Halpern J., ten Hoeve J., et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13(2):247-254.
20. Skorski T., Kanakaraj P., Nieborowska-Skorska M., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86(2):726-736.
21. Salgia R., Uemura N., Okuda K., et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995, 270(49):29145-29150.
22. Barnes D.J., Palaiologou D., Panousopoulou E., et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005, 65(19):8912-8919.
23. Barnes D.J., Schultheis B., Adedeji S., et al. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005, 24(42):6432-6440.
24. Modi H., McDonald T., Chu S., et al. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 2007, 109(12):5411-5421.
25. Perrotti D., Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007, 13(6):1638-1642.
26. Abrahamsson A.E., Geron I., Gotlib J., et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A 2009, 106(10):3925-3929.
27. Klein F., Feldhahn N., Herzog S., et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006, 25(7):1118-1124.
28. Yu J., Vodyanik M.A., Smuga-Otto K., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.
29. Viswanathan S.R., Powers J.T., Einhorn W., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009, 41(7):843-848.
30. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103(11):4010-4022.
31. Shet A.S., Jahagirdar B.N., Verfaillie C.M. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002, 16(8):1402-1411.
32. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002, 2(5):351-360.
33. Majsterek I., Blasiak J., Mlynarski W., et al. Does the BCR/ABL-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?. Cell Biol Int 2002, 26(4):363-370.
34. Slupianek A., Hoser G., Majsterek I., et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002, 22(12):4189-4201.
35. Sattler M., Verma S., Shrikhande G., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000, 275(32):24273-24278.
36. Fioretos T., Strombeck B., Sandberg T., et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 1999, 94(1):225-232.
37. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88(3):323-331.
38. Sawyers C.L., Callahan W., Witte O.N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992, 70(6):901-910.
39. Collins S., Groudine M. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 1982, 298(5875):679-681.
40. Virtaneva K., Wright F.A., Tanner S.M., et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 2001, 98(3):1124-1129.
41. Medina J., Kantarjian H., Talpaz M., et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003, 98(9):1905-1911.
42. Mitani K., Ogawa S., Tanaka T., et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994, 13(3):504-510.
43. Nakamura T., Largaespada D.A., Lee M.P., et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 1996, 12(2):154-158.
44. Cuenco G.M., Ren R. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 2001, 20(57):8236-8248.
45. Dash A.B., Williams I.R., Kutok J.L., et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A 2002, 99(11):7622-7627.
46. Ito T., Kwon H.Y., Zimdahl B., et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010, 466(7307):765-768.
47. Collins S.J., Howard M., Andrews D.F., et al. Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood 1989, 73(4):1028-1032.
48. Ahuja H., Bar-Eli M., Advani S.H., et al. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A 1989, 86(17):6783-6787.
49. Sill H., Goldman J.M., Cross N.C. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995, 85(8):2013-2016.
50. Neviani P., Santhanam R., Trotta R., et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8(5):355-368.
51. Chang J.S., Santhanam R., Trotta R., et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007, 110(3):994-1003.
52. Perrotti D., Cesi V., Trotta R., et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002, 30(1):48-58.
53. Wagner K., Zhang P., Rosenbauer F., et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A 2006, 103(16):6338-6343.
54. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275(5307):1784-1787.
55. Rask K., Nilsson A., Brannstrom M., et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003, 89(7):1298-1304.
56. Uematsu K., He B., You L., et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003, 22(46):7218-7221.
57. Guo Z., Dose M., Kovalovsky D., et al. {beta}-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 2007, 109(12):5463-5472.
58. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351(7):657-667.
59. Passegue E., Wagner E.F., Weissman I.L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004, 119(3):431-443.
60. Hoshino K., Quintas-Cardama A., Radich J., et al. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res 2009, 33(10):1361-1366.
61. Hromas R., Collins S.J., Hickstein D., et al. A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem 1991, 266(22):14183-14187.
62. Gaboli M., Kotsi P.A., Gurrieri C., et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev 2001, 15(13):1625-1630.
63. Perrotti D., Melotti P., Skorski T., et al. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol 1995, 15(11):6075-6087.
64. Guaita S., Puig I., Franci C., et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 2002, 277(42):39209-39216.
65. Le Mee S., Fromigue O., Marie P.J. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Exp Cell Res 2005, 302(1):129-142.
66. Miyoshi A., Kitajima Y., Sumi K., et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 2004, 90(6):1265-1273.
67. Kusano S., Raab-Traub N. I-Mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol 2002, 22(18):6393-6405.
68. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303(5663):1483-1487.
69. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453(7191):110-114.
70. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115(20):4715-4726.
71. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458(7239):776-779.
72. Perrotti D., Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008, 27(2):159-168.
73. Copland M., Pellicano F., Richmond L., et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111(5):2843-2853.
74. Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008, 49(4):610-614.
75. Bumm T., Muller C., Al-Ali H.K., et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101(5):1941-1949.
76. O'Dwyer M.E., Gatter K.M., Loriaux M., et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003, 17(3):481-487.
77. Biernaux C., Loos M., Sels A., et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86(8):3118-3122.
78. Bose S., Deininger M., Gora-Tybor J., et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92(9):3362-3367.
79. Oehler V.G., Yeung K.Y., Choi Y.E., et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009, 114(15):3292-3298.
80. Oehler V.G., Qin J., Ramakrishnan R., et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2009, 23(2):396-399.